SPL 0.00% 10.5¢ starpharma holdings limited

Starpharma and Glioblastoma and Dep Docetaxel and Patrys, page-6

  1. 108 Posts.
    lightbulb Created with Sketch. 13
    Because it wasn't involved.

    From a quick look, PAB's announcement says that their nanoparticles conjugated to PAT-DX1 (PAT-DX1-NP) has shown improved targeting of glioblastomas in mice. They are excited because this suggests it might be used both to deliver their PAT-X1 drug but also as a vector for introducing other targeted treatments to brain tumours.

    AB is pointing to their 2016 post, which refers to the DEP Docetaxel clinical program phase 1 clinical trial, which showed efficacy signals on a variety of tumour types including glioblastomas.

    The PAB announcement is unrelated to SPL (unless PAB is a silent partner of SPL using DEP but I don't know anything to suggest they are).

    AB is just drawing a comparison.
    Last edited by Chip343: Fixed some spelling 19/03/18
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
(20min delay)
Last
10.5¢
Change
0.000(0.00%)
Mkt cap ! $43.90M
Open High Low Value Volume
10.5¢ 11.5¢ 10.0¢ $110.6K 1.006M

Buyers (Bids)

No. Vol. Price($)
1 83046 10.5¢
 

Sellers (Offers)

Price($) Vol. No.
11.0¢ 30000 1
View Market Depth
Last trade - 16.10pm 15/11/2024 (20 minute delay) ?
SPL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.